Announcement PDF All Registry communications to: Automic Group GPO Box 5193 Sydney NSW 2001 Telephone (free call within Australia): 1300 288 664 ASX Code: ACW 28 October 2026 Upcoming Annual General Meeting of Shareholders Dear Shareholder Actinogen Medical Limited ACN 086 778 476 (ASX: ACW or “the Company”), advises the 2026 Annual General Meeting will be held at K&L Gates, Level 31, 1 O’Connell Street, Sydney, New South Wales and online at www.investor.automic.com.au on Monday, 30 November 2026 at 10.00 am (Sydney time) (Meeting). Notice of Meeting The Notice of Meeting and Explanatory Memorandum (Notice) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (Shareholders) from the Company’s website at https://actinogen.com.au or the Company's ASX market announcements platform at www.asx.com.au (ASX: ACW). In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy. Voting by Proxy For further information on the online proxy lodgment process, or if you require a hard copy Proxy Form, please contact the Company’s Share Registry, Automic Registry Services (Automic), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas). Shareholder queries in relation to the Meeting Shareholders can contact the Company Secretary with any questions prior to the meeting via email at info@actinogen.com.au. Copies of all Meeting related material including the Notice and the Company's Annual Report, are available to download from the Company’s website and the Company's ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company’s website. Authorised for ASX release by the Company Secretary. [LOG Online scan the QR code below using your smartphone Lodge your Proxy vote online at https://singleholding.automic.com.au/login by following the below instructions: 1. Login to the Automic website using the holding details as shown on your holding statement. 2. Click on ‘Meetings’ - ‘Vote’. To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement. Actinogen Medical Limited ACN 086 778 476 NOTICE OF 2026 ANNUAL GENERAL MEETING TIME: 10.00 am (AEDT) DATE: Monday, 30 November 2026 PLACE: The Annual General Meeting will be held as a hybrid meeting In person: K&L Gates, Level 31, 1 O’Connell Street, Sydney NSW 2000 Online: At www.investor.automic.com.au Further information on the online voting process can be found in the Virtual Meeting Registration and Voting Guide online at https://www.automicgroup.com.au/virtual-agms. In accordance with section 110D(1) of the Corporations Act, the Company will not be sending hard copies of this Notice of Meeting to shareholders unless a shareholder has requested a hard copy of this Notice or made an election for the purposes of section 110E of the Corporations Act to receive documents from the Company in physical form. This Notice can be viewed and downloaded from the Company's Investor Hub at https://investors.actinogen.com.au/annual-general-meeting or the ASX at www.asx.com.au. This Notice of Annual General Meeting and Explanatory Memorandum should be read in its entirety. If you are in doubt as to how to vote on any of the Resolutions, you should seek advice from your accountant, solicitor or other professional adviser without delay. 2 ACTINOGEN MEDICAL LIMITED ACN 086 778 476 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the annual general meeting of the shareholders of Actinogen Medical Limited ACN 086 778 476 (Company or Actinogen) will be held at K&L Gates, Level 31, 1 O’Connell Street, Sydney NSW 2000 and online at www.investor.automic.com.au on Monday, 30 November 2026 at 10.00 am (AEDT) for the purpose of transacting the business outlined in this Notice of Annual General Meeting. Registration will be available from 9.30 am (AEDT). This Notice describes the business that will be proposed and sets out the procedures for Shareholder participation and voting. Subject to any changes, all Shareholders are entitled to attend the Meeting at the time, date and place set out above and vote in person or online. To enable participation by Shareholders in the Meeting without physical attendance, the Company is pleased to provide Shareholders with the opportunity to attend and participate in the Meeting through the Automic online platform. Shareholders will be able to watch, listen, ask questions and vote at the Meeting online via this platform. Further information on how to attend and vote via this platform is included in the instructions set out in the ‘Meeting Attendance and Voting Information’ section of this Notice. The Company will update Shareholders if changing circumstances will impact the planning or arrangements for the Meeting by way of announcement on ASX and the details will also be made available on our Investor Hub portal at https://investors.actinogen.com.au/annual-general-meeting. Please note that additional information concerning the proposed Resolutions is contained in the Explanatory Memorandum that accompanies and forms part of this Notice. Voting Exclusions to some of the following Resolutions appear below and are deemed to form part of this Notice. Terms and abbreviations used in this Notice are defined in the Glossary. GENERAL BUSINESS FINANCIAL STATEMENTS AND REPORTS To receive and consider the financial statements and the reports of the Directors and of the auditors for the year ended 30 June 2026. Shareholders should consider this document and raise any matters of interest with the Directors when this item is being considered. No Resolution is required to be moved in respect of this item of business. 1. RESOLUTION 1: ADOPTION OF REMUNERATION REPORT During this item of business, Shareholders at the Meeting may comment on and ask questions about the Remuneration Report which appears in the Company's 2026 Annual Report. To consider and, if thought fit, pass the following resolution as an ordinary resolution: "That, for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the year ended 30 June 2026 as set out in the Company's Annual Report for the year ended 30 June 2026 be adopted.” Note: The vote on this Resolution is advisory only and does not bind the Directors or the Company. 3 2. RESOLUTION 2: RE-ELECTION OF DR GEORGE MORSTYN To consider and, if thought fit, to pass the following resolution as an ordinary resolution: "That pursuant to the Company's Constitution and for all other purposes, shareholders approve the re-election of Dr George Morstyn as a Non-Executive Director of the Company, who pursuant to clause 13.3(b) of the Company's Constitution is retiring by rotation and being eligible offers himself for re-election." 3. RESOLUTION 3: RE-ELECTION OF DR NICKI VASQUEZ To consider and, if thought fit, to pass the following resolution as an ordinary resolution: "That pursuant to the Company's Constitution and for all other purposes, shareholders approve the re-election of Nicki Vasquez as a Non-Executive Director of the Company, who pursuant to clause 13.3(b) of the Company's Constitution is retiring by rotation and being eligible offers herself for re-election.” 4. RESOLUTION 4: APPROVAL OF INCREASED PLACEMENT CAPACITY To consider and, if thought fit, to pass the following resolution as a special resolution: "That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, shareholders approve the increase in the capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions stated in the Explanatory Memorandum which accompanies and forms part of this Notice of Meeting.” Note: If as at the time of the Meeting, the Company: (a) is included in the S&P/ASX 300 Index; and (b) has a market capitalisation of greater than AU$300 million, then this Resolution 4 will be withdrawn. 5. RESOLUTION 5: APPROVAL OF OMNIBUS PLAN To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.2 Exception 13(b), sections 200B, 200E and 259B(2) of the Corporations Act and for all other purposes, shareholders approve the Company's Omnibus Plan, a copy of which is available for inspection at the registered office of the Company (during normal business hours)." 6. RESOLUTION 6: APPROVAL TO AMEND CONSTITUTION - RENEWAL OF THE PROPORTIONAL BID PROVISIONS To consider and, if thought fit, to pass the following resolution as a special resolution: "That pursuant to sections 136(2) and 648G(4) of the Corporations Act and for all other purposes, shareholders approve the amendment of the Company’s Constitution by renewing clause 11, being the proportional bid provisions of the Constitution, as set out in the Explanatory Memorandum which accompanies and forms part of this Notice of Meeting." OTHER BUSINESS To consider any other business that may lawfully be brought forward in accordance with the Constitution of the Company or the law. VOTING EXCLUSION STATEMENTS In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the resolution by or on behalf of the following named person or class of persons and an associate of those persons: 4 Resolution 4: Approval of Increased Placement Capacity If at the time the approval of Resolution 4 is sought the Company is proposing to make an issue of securities under rule 7.1A.2, any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company. Resolution 5: Approval of Omnibus Plan A person who is eligible to participate in the Omnibus Plan. The above voting exclusions do not apply to a vote cast in favour of the relevant Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that they are not excluded from voting, and are not an associate of a person excluded from voting, on the Resolution; and (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. VOTING PROHIBITION STATEMENTS Resolution 1: Adoption of Remuneration Report In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution 1 if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution 1. However, the above prohibition does not apply if: (c) the proxy is the Chair; and (d) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution 1 is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Resolution 5: Approval of Omnibus Plan In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution 5 if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution 5. However, the above prohibition does not apply if: (c) the proxy is the Chair; and (d) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution 5 is connected directly or indirectly with remuneration of a member of the Key Management Personnel. 5 By order of the Board Peter Webse Company Secretary 19 October 2026 MEETING ATTENDANCE AND VOTING INFORMATION Shareholders can vote by either: • attending the Meeting and voting in person or online (including by attorney) or, in the case of corporate Shareholders, by appointing a corporate representative to attend and vote; or • appointing a proxy to attend and vote on their behalf using the Proxy Form accompanying this Notice and by submitting their proxy appointment and voting instructions in person, by post or electronically via the internet. Attending and voting in person Shareholders, or their attorneys, who plan to attend the Meeting in person are asked to arrive at the venue 15 minutes prior to the time designated for the Meeting, if possible, so that their holding may be checked against the Company’s share register and their attendance recorded. Venue and Voting Information The Company is pleased to provide Shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic. Shareholders that have an existing account with Automic will be able to watch, listen and vote online. Shareholders who do not have an account with Automic are strongly encouraged to register for an account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting. An account can be created via the following link investor.automic.com.au and then clicking on “register” and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic. To access the virtual Meeting on the day: 1. Open your internet browser and go to investor.automic.com.au 2. Login with your username and password or click “register” if you haven’t already created an account. Shareholders are encouraged to create an account prior to the start of the Meeting to ensure there is no delay in attending the virtual Meeting. 3. After logging in, a banner will display at the bottom of your screen to indicate that the Meeting is open for registration, click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu bar to join the Meeting. 4. Click on “Join Meeting” and follow the prompts on screen to register and vote. Shareholders will be able to vote (see the “Voting virtually at the Meeting” section of this Notice below) and ask questions at the virtual Meeting. Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to Peter Webse, Company Secretary at pwebse@governancecorp.com.au at least 48 hours before the Meeting. The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business. Voting virtually at the Meeting Shareholders who wish to vote virtually on the day of the Meeting can do so by logging into the Automic shareholder portal. 1. Open your internet browser and go to investor.automic.com.au 2. Login using your username and password. If you do not already have an account, click “Register” and follow the prompts. Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform. 3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click “Register”. Alternatively, select Meetings from the left-hand menu. 4. Click on “Join Meeting” and follow the prompts. 5. When the Chair of the Meeting declares the poll open, select the “Voting” dropdown menu on the right-hand side of your screen. 6. Select either the “Full” or “Allocate” option to access your electronic voting card. 7 7. Follow the prompts to record your voting direction for each resolution and click “Submit votes”. For allocated votes, the number of votes submitted must not exceed your remaining available units. Important: Votes cannot be amended once submitted. For further information on the live voting process please see the Virtual Meeting Registration and Voting Guide at https://www.automicgroup.com.au/virtual-agms/ It is recommended that Shareholders wishing to attend the Meeting log in from 15 to 30 minutes prior to the scheduled start time. Attorneys To be effective, a certified copy of the Power of Attorney, or the original Power of Attorney, must be received by the Company in the same manner, and by the same time as outlined for Proxy Forms below. Voting by a corporation A Shareholder that is a corporation may appoint an individual to act as its representative and vote in person at the Meeting. The appointment must comply with the requirements of section 250D of the Corporations Act. The representative should bring to the Meeting evidence of his or her appointment, including any authority under which it is signed. Changes to Meeting arrangements The Company will notify Shareholders via the Company’s website at www.orthocell.com and the Company’s ASX Announcement Platform at www.asx.com.au (ASX: ACW) if changing circumstances impact the planning or arrangements for the Meeting. Voting by proxy • A Shareholder entitled to attend and vote is entitled to appoint not more than two proxies. Each proxy will have the right to vote on a poll and also to speak at the Meeting. • The appointment of the proxy may specify the proportion or the number of votes that the proxy may exercise. Where more than one proxy is appointed and the appointment does not specify the proportion or number of the Shareholder’s votes each proxy may exercise, the votes will be divided equally among the proxies (i.e. where there are two proxies, each proxy may exercise half of the votes). • A proxy need not be a Shareholder. • The proxy can be either an individual or a body corporate. • If a proxy is not directed how to vote on an item of business, the proxy may generally vote, or abstain from voting, as they think fit. However, where a voting prohibition statement applies to a voter under this Notice (Restricted Voter) and a Restricted Voter is appointed as a proxy, the proxy may only vote on Resolutions 1 and 5 in accordance with a direction on how the proxy is to vote or, if the proxy is the Chair of the Meeting, where the appointment expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel. • Should any resolution, other than those specified in this Notice, be proposed at the Meeting, a proxy may vote on that resolution as they think fit. • If a proxy is instructed to abstain from voting on an item of business, they are directed not to vote on the Shareholder’s behalf on the poll and the Shares that are the subject of the proxy appointment will not be counted in calculating the required majority. • Shareholders who return their Proxy Forms with a direction on how to vote, but who do not nominate the identity of their proxy, will be taken to have appointed the Chair of the Meeting as their proxy to vote on their behalf. If a Proxy Form is returned but the nominated proxy does not attend the Meeting, the Chair of the Meeting will act in place of the nominated proxy and vote in accordance with any instructions. Proxy appointments in favour of the Chair of the Meeting, the secretary or any Director that do not contain a direction on how to vote will be used, where possible, to support each of the Resolutions proposed in this Notice, provided they are entitled to cast votes as a proxy under the voting exclusion rules which apply to some of the proposed Resolutions. These rules are explained in this Notice. • To be effective, proxies must be received by 10.00 am (AEDT) on Saturday, 28 November 2026. Proxies received after this time will be invalid. • To vote by proxy, please use one of the following methods:  by returning a completed Proxy Form by post to: Automic GPO Box 5193 Sydney NSW 2001  by returning a completed Proxy Form and delivering it in person at: 8 Automic Level 5, 126 Phillip Street Sydney NSW 2000  by faxing a completed Proxy Form to +61 2 8583 3040; by emailing a completed Proxy Form to: meetings@automicgroup.com.au or  by recording the proxy appointment and voting instructions via the internet at https://portal.automic.com.au/investor/home • The Proxy Form must be signed by the Shareholder or the Shareholder’s attorney. Proxies given by corporations must be executed in accordance with the Corporations Act. Where the appointment of a proxy is signed by the appointer’s attorney, a certified copy of the Power of Attorney, or the power itself, must be received by the Company at the above address, or by facsimile, and by 10.00 am (AEDT) on Saturday, 28 November 2026. If facsimile transmission is used, the Power of Attorney must be certified. Shareholders who are entitled to vote In accordance with paragraphs 7.11.37 and 7.11.38 of the Corporations Regulations, the Board has determined that a person’s entitlement to vote at the Meeting will be the entitlement of that person set out in the register of Shareholders as at 10.00 am (AEDT) on Saturday, 28 November 2026. 9 ACTINOGEN MEDICAL LIMITED ACN 086 778 476 EXPLANATORY MEMORANDUM This Explanatory Memorandum has been prepared for the information of Shareholders in connection with the business to be conducted at the Annual General Meeting of Shareholders to be held at K&L Gates, Level 31, 1 O’Connell Street, Sydney NSW 2000 and online at www.investor.automic.com.au on Monday, 30 November 2026 at 10.00 am (AEDT) (Meeting). The purpose of this Explanatory Memorandum is to provide information that the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions in the Notice of Meeting. REPORTS AND ACCOUNTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2026 The Corporations Act requires the Company to provide before the Annual General Meeting, the Financial Report, Directors' Report (including the Remuneration Report) and the Auditor's Report for the financial year ended 30 June 2026. Shareholders will be offered the opportunity to discuss the Financial Report, Directors’ Report and Auditor’s Report at the Meeting. Copies of these reports can be found on the Company’s Investor Hub at https://actinogen.com.au/about-us/#annual_reports. There is no requirement for Shareholders to approve the Financial Report, Directors’ Report and Auditor’s Report. Shareholders will be offered the following opportunities: (a) discuss the Annual Report for the financial year ended 30 June 2026; (b) ask questions or make comments on the management of the Company; and (c) ask the auditor questions. In addition to taking questions at the Meeting, written questions to the Chair about the management of the Company, or to the Company’s auditor about: (a) the preparation and content of the Auditor’s Report; (b) the conduct of the audit; (c) accounting policies adopted by the Company in relation to the preparation of the financial statements; and (d) the independence of the auditor in relation to the conduct of the audit, may be submitted no later than 5 business days before the Meeting to the Company Secretary at the Company’s registered office. 1. Resolution 1 – Adoption of Remuneration Report 1.1 Corporations Act Under the Corporations Act, listed entities are required to put to the vote a resolution that the Remuneration Report section of the Directors’ Report be adopted. This Remuneration Report can be found in the Company’s 2026 Annual Report. It sets out a range of matters relating to the remuneration of Directors, the Company Secretary and senior executives of the Company. A vote on this Resolution 1 is advisory only and does not bind the Directors or the Company. 10 The Corporations Act provides that: (a) members of the Key Management Personnel whose remuneration details are included in the Remuneration Report (and any closely related party of those members) are not permitted to vote on a resolution to approve the Remuneration Report, and (b) if the vote to approve the Remuneration Report receives a “no” vote by at least 25% of the votes cast, this will constitute a “first strike”. The Company's current "strike" count is zero. If a “first strike” was to occur at the 2026 Annual General Meeting: (a) the Company’s subsequent Remuneration Report (in other words, the Company’s Remuneration Report to be included in the 2027 Annual Report) must include an explanation of the Board’s proposed action in response to a 2026 “no vote” or an explanation of why no action has been taken; and (b) if the Company’s subsequent (i.e. 2027) Remuneration Report also receives a “no vote” at the 2027 Annual General Meeting of at least 25% of the votes cast, then Shareholders at the 2027 Annual General Meeting will be asked (at that 2027 Annual General Meeting) to vote on whether or not the Company is to hold another general Shareholder’s meeting (within the following 90 days) to vote on a “spill resolution” under section 250V of the Corporations Act. 1.2 Board recommendation As set out in the Notice of Meeting, any member of the Key Management Personnel whose remuneration details are included in the Remuneration Report, together with a closely related party of those members, are excluded from casting a vote on Resolution 1. Accordingly, the Board abstains from making a recommendation in relation to Resolution 1. The Chair intends to exercise all undirected proxies in favour of Resolution 1. 2. Resolution 2: Re-election of Dr George Morstyn 2.1 Background Clause 13.3(b) of the Company’s Constitution provides that no Director may hold office for a period in excess of 3 years, or beyond the third annual general meeting following the Director’s election, whichever is the longer, without submitting themself for re-election. Dr Morstyn was last elected as an Independent Non-Executive Director on 17 November 2023, and being eligible, offers himself for re-election. 2.2 Director CV Appointment date 1 December 2017 Qualifications Dr Morstyn is a medical graduate of Monash University (Australia) and obtained a Fellowship at the National Cancer Institute in the USA. He is a Member of the Australian Institute of Company Directors and a Fellow of the Australian Academy of Technological Sciences and Engineering Experience Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had overall 11 responsibility globally for drug development in all therapeutic areas including neuroscience and Amgen Inc and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn’s tenure. Prior to joining Amgen Inc, Dr Morstyn was the principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (CSF). The CSFs were subsequently approved and launched and were a major medical breakthrough that have been used to reduce the side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide. The CFSs have become billion dollar drugs. Other current directorships Since returning to Australia, Dr Morstyn has been a Non-Executive Director of various not-for-profit companies, including many biotechnology companies. Dr Morstyn has held no other ASX-listed directorships during the past three years. Dr Morstyn is currently an advisor to Symbio (Tokyo) and TroBio. Special responsibilities Member of Audit and Risk Committee 2.3 Board recommendation The Directors (other than Dr Morstyn) recommend that Shareholders vote in favour of this Resolution 2. The Chair intends to exercise all undirected proxies in favour of Resolution 2. 3. Resolution 3: Re-election of Dr Nicki Vasquez 3.1 Background Clause 13.3(b) of the Company’s Constitution provides that no Director may hold office for a period in excess of 3 years, or beyond the third annual general meeting following the Director’s election, whichever is the longer, without submitting themself for re-election. Dr Vasquez was elected as an Independent Non-Executive Director on 17 November 2023, and being eligible, offers herself for re-election. 3.2 Director CV Appointment date 1 March 2023 Qualifications Dr Vasquez obtained her doctoral degree in immunology. Dr Vasquez is US-based and strengthens the Actinogen Board with skills and experience in partnering and alliance management, strategic licensing, as well as a strong depth of knowledge in clinical development. Experience Dr Vasquez is an immunologist and biopharmaceutical executive with more than 25 years of biopharmaceutical discovery research and development experience. Dr Vasquez most recently served as Chief Portfolio Strategy & Alliance Officer at Sutro Biopharma, a clinical stage oncology company in San Francisco where she was responsible for program management, portfolio strategy and alliance manage